N
17.22
-0.54 (-3.04%)
| Previous Close | 17.76 |
| Open | 17.73 |
| Volume | 91,079 |
| Avg. Volume (3M) | 266,208 |
| Market Cap | 245,593,360 |
| Price / Sales | 403.76 |
| Price / Book | 0.980 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -9,701.19% |
| Diluted EPS (TTM) | -4.36 |
| Total Debt/Equity (MRQ) | 4.01% |
| Current Ratio (MRQ) | 21.03 |
| Operating Cash Flow (TTM) | -69.73 M |
| Levered Free Cash Flow (TTM) | -40.39 M |
| Return on Assets (TTM) | -21.97% |
| Return on Equity (TTM) | -34.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Neurogene Inc. | Bearish | Bearish |
AIStockmoo Score
1.3
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 5.0 |
| Average | 1.25 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.28% |
| % Held by Institutions | 115.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Craig-Hallum, 190.36%) | Buy |
| Median | 35.50 (106.16%) | |
| Low | 24.00 (Baird, 39.37%) | Hold |
| Average | 36.25 (110.51%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 18.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 17 Jun 2025 | 50.00 (190.36%) | Buy | 18.42 |
| BMO Capital | 12 Jun 2025 | 26.00 (50.99%) | Buy | 20.40 |
| 20 May 2025 | 22.00 (27.76%) | Buy | 18.55 | |
| Baird | 16 May 2025 | 24.00 (39.37%) | Hold | 17.99 |
| HC Wainwright & Co. | 13 May 2025 | 45.00 (161.32%) | Buy | 15.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Jul 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Jun 2025 | Announcement | Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome |
| 06 Jun 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 16 May 2025 | Announcement | Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV |
| 09 May 2025 | Announcement | Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates |
| 08 May 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 28 Apr 2025 | Announcement | Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |